Home
Companies
Catena Biosciences

Catena Biosciences

Using protein coupling to build new therapies

Catena’s technology lets us attach any two proteins together using an enzyme and the native amino acids tyrosine and cysteine within target proteins. It is a true platform technology because it enables the joining of any two soluble proteins together with minimal engineering and without restrictions due to protein size or complexity. Our work has already been used to modify cancer specific antibodies, CRISPR proteins and even cell surfaces. Our ability to produce modular protein therapeutics in a fraction of the time allows for true library creation across the therapeutics spectrum from oncology, vaccines, inflammatory disease and beyond.

Catena Biosciences
Founded:2020
Team Size:7
Location:Berkeley, CA
Group Partner:Jared Friedman

Active Founders

Marco Lobba

CEO and Co-Founder at Catena Biosciences. Marco completed his Ph.D. at UC Berkeley jointly between the labs of Matt Francis and Jennifer Doudna. When not starting a company or doing science Marco likes to backpack, rock climb, kayak, and just about any activity that involves not being inside.

Matthew Francis

Matthew Francis
Matthew Francis
Catena Biosciences